Skip to main content

Mechanism of Action of an Interleukin (IL)–23 Inhibitor Monoclonal Antibody in Moderate to Severe Plaque Psoriasis and Active Psoriatic Arthritis

  • Sponsored by Janssen Biotech, Inc.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.